Colectomy for Cancer in the Elderly by Laparoscopy or Laparotomy (CELL)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03033719 |
Recruitment Status : Unknown
Verified January 2018 by Assistance Publique - Hôpitaux de Paris.
Recruitment status was: Recruiting
First Posted : January 27, 2017
Last Update Posted : January 12, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Colonic Cancer | Procedure: Laparotomy Procedure: Laparoscopy | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 276 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Multicenter Randomized Trial Comparing Laparoscopy and Laparotomy for Colon Cancer Surgery in Patients Older Than 75 Years |
Actual Study Start Date : | July 4, 2017 |
Estimated Primary Completion Date : | April 2020 |
Estimated Study Completion Date : | June 2020 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Laparotomy
Open surgery
|
Procedure: Laparotomy
Open surgery
Other Name: Open surgery |
Experimental: Laparoscopy
Minimally invasive surgery
|
Procedure: Laparoscopy
Minimally invasive surgery
Other Name: Minimally invasive surgery |
- Global postoperative morbidity in both arms [ Time Frame: At 30 days after the surgery ]Postoperative morbidity is defined as any surgical or medical complications occurring up to 30 days after surgery. It will be collected using a standardized collection form during hospitalization and eventual subsequent consultations in case of patient discharge before then
- Postoperative mortality [ Time Frame: Evaluated at 30 days and at 90 days after the surgery ]Death from any cause
- Rate of readmission [ Time Frame: Within the 30 days after discharge of the patient ]Defined as any rehospitalization whatever the cause
- Number of examined lymph nodes [ Time Frame: At surgery ]Quality of surgical resection : Number of examined lymph nodes
- Type of resection (R0 or R1) [ Time Frame: At surgery ]Quality of surgical resection : Type of resection (R0 or R1)
- Pathological evaluation of mesocolic resection quality [ Time Frame: At surgery ]Quality of surgical resection : Pathological evaluation of mesocolic resection quality
- Health-related quality of life : Quality of Life Questionnaires (EORTC QLQ-C30) [ Time Frame: At randomization and three months postoperatively ]Health-related quality of life : Quality of Life Questionnaires (EORTC QLQ-C30)
- Health-related quality of life : Quality of Life Questionnaires (EORTC QLQ-CR29) [ Time Frame: At randomization and three months postoperatively ]Health-related quality of life : Quality of Life Questionnaires (EORTC QLQ-CR29)
- Mini Mental State (MMS) Examination or Folstein test [ Time Frame: Before randomization and three months postoperatively ]Evolution of geriatric scores : The Mini Mental State (MMS) Examination or Folstein test; (Comprehensive geriatric assessment performed by a geriatrician on each site)
- Katz Activities of Daily Living (ADL) scale [ Time Frame: Before randomization and three months postoperatively ]Evolution of geriatric scores :The Katz Activities of Daily Living (ADL) scale (Comprehensive geriatric assessment performed by a geriatrician on each site)
- Geriatric Depression Scale (GDS) [ Time Frame: Before randomization and three months postoperatively ]Evolution of geriatric scores :The Geriatric Depression Scale (GDS) (Comprehensive geriatric assessment performed by a geriatrician on each site)
- Timed Get-up-and-go (TGUG) [ Time Frame: Before randomization and three months postoperatively ]Evolution of geriatric scores :The Timed Get-up-and-go (TGUG) test (Comprehensive geriatric assessment performed by a geriatrician on each site)
- To establish a specific molecular classification of colon cancer in the elderly from expression chips [ Time Frame: within the 15 years after the tumor sampling ]To establish a specific molecular classification of colon cancer in the elderly from expression chips (Ancillary studies will be conducted from formalin fixed paraffin embedded (FFPE) tumor samples from our cohort)
- To establish associations between molecular subtypes, the clinical and histological factors and relevant genetic alterations [ Time Frame: within the 15 years after the tumor sampling ]To establish associations between molecular subtypes, the clinical and histological factors and relevant genetic alterations (Ancillary studies will be conducted from formalin fixed paraffin embedded (FFPE) tumor samples from our cohort)
- To establish a possible link between these molecular subtypes and overall survival of patients [ Time Frame: within the 15 years after the tumor sampling ]
To establish a possible link between these molecular subtypes and overall survival of patients.
(Ancillary studies will be conducted from formalin fixed paraffin embedded (FFPE) tumor samples from our cohort)
- To compare our molecular classification with the different classifications already published in the literature on colorectal cance [ Time Frame: within the 15 years after the tumor sampling ]To compare our molecular classification with the different classifications already published in the literature on colorectal cancer (Ancillary studies will be conducted from formalin fixed paraffin embedded (FFPE) tumor samples from our cohort)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 75 Years and older (Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥ 75 years
- Histologically proven colonic adenocarcinoma (> 15 cm from the anal margin) or precancerous colonic lesion non endoscopically resectable
- Uncomplicated colonic tumor (no preoperative suspicion of invasion of adjacent structures as assessed by CT-scan (cT4), no tumoral perforation, or tumoral obstruction, or abscess, or hemorrhage)
- No previous colonic cancer within the 5 last years
- No peritoneal carcinosis on CT-scan
- Patient able to fill in an auto-questionnaire alone or with some help
- MMS (Mini Mental Score) ≥ 15
- Given oral consent (formal informed consent is not required by French law for accepted procedures)
Exclusion Criteria:
- Rectal cancer (≤ 15 cm from the anal margin)
- Locally advanced (cT4) or complicated tumor requiring extended resection or emergency surgery
- Synchronous colonic cancer
- - Scheduled need for synchronous intra-abdominal surgery, including surgery for liver metastases
- Absolute contraindications to general anesthesia or prolonged pneumoperitoneum
- Patient not able to tolerate colon surgery according to the global comprehensive geriatric assessment
- Estimated life expectancy less than 6 months
- Patient under guardianship
- Other known active cancer (except nonmelanomatous skin cancer)
- Patient not affiliated to the social security system
- Previous colonic resection

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03033719
Contact: Gilles MANCEAU, M.D., PhD., | 00331 42 17 56 51 | gilles.manceau@aphp.fr |
France | |
Groupe Hospitalier Pitié Salpêtrière | Recruiting |
Paris, France, 75013 | |
Contact: Gilles MANCEAU, MD gilles.manceau@aphp.fr |
Principal Investigator: | Gilles MANCEAU, M.D., PhD., | Assistance Publique - Hôpitaux de Paris |
Responsible Party: | Assistance Publique - Hôpitaux de Paris |
ClinicalTrials.gov Identifier: | NCT03033719 |
Other Study ID Numbers: |
K130901 2016-A00312-49 ( Other Identifier: ID RCB ) |
First Posted: | January 27, 2017 Key Record Dates |
Last Update Posted: | January 12, 2018 |
Last Verified: | January 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Colorectal Surgery Geriatrics Digestive Oncology Colon cancer |
Elderly patients Laparoscopy Laparotomy Morbidity |
Colonic Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site |
Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases |